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ABSTRACT 
Drug-eluting stents (DESs) are the treatment of choice for obstructive coronary artery disease when percutaneous 
intervention is feasible. However, late stent thrombosis seems to occur more frequently with DESs and is closely 
associated with the discontinuation of dual antiplatelet therapy. We report a case of very late stent thrombosis 
after discontinuation of dual antiplatelet therapy. The patient suffered from acute myocardial infarction (MI) 
and underwent bare metal stent (BMS) implantation in the left anterior descending artery (LAD) five years prior 
to presentation. Three years after BMS implantation, he presented again with acute MI and had a DES implanted 
in the right coronary artery (RCA). He ran out of his medication, but failed to refill his prescription. Sixteen 
days after discontinuing medication, he experienced an episode of chest pain and was taken to the cardiac cathe-
terization laboratory, where he was found to have thrombosis in the DES, but no thrombosis in the BMS. It is 
possible that DESs are more vulnerable to late thrombosis than are BMSs, supporting the use of prolonged dual 
antiplatelet therapy in patients treated with DESs. The patient was successfully treated with balloon angioplasty 
and thrombus aspiration without complications. (Korean Circ J 2009;39:205-208) 
 





In recent years, drug-eluting stents (DESs) have been 
shown to dramatically reduce the rate of restenosis and 
the need for repeat revascularization.
1-3) Despite these 
promising results, late stent thrombosis seems to occur 
more frequently with DESs and seems to be closely as-
sociated with the discontinuation of dual aspirin/thieno-
pyridine derivative (usually clopidogrel) antiplatelet ther-
apy.
1-4) We report a case of late DES thrombosis after 




A 49-year-old man was transferred to the emergency 
department complaining of squeezing chest pain that 
had increased in severity over the past four days. Five 
years prior to presentation, he had undergone percuta-
neous coronary intervention (PCI) for acute myocardial 
infarction (MI), along with implantation of a bare metal 
stent (BMS) (3.5×28 mm Arthos Inert Stent, AMG, 
Korea) in the left anterior descending artery (LAD) (Fig. 
1). Six months later, he developed angina and underwent 
balloon angioplasty for in-stent restenosis (Fig. 2). Two 
years after that, he had a paclitaxel-eluting stent (2.75×
32 mm Taxus Stent, Boston Scientific, USA) placed in 
the right coronary artery (RCA) after suffering another 
acute MI (Fig. 3). The patient was treated with dual an-
tiplatelet therapy: aspirin (100 mg daily) and clopidogrel 
(75 mg daily). He ran out of his medication, but failed 
to refill his prescription. Sixteen days after discontinu-
ing medication, he developed chest pain and presented 
to the emergency department. An electrocardiogram 
(ECG) performed at that time showed new ST-segment 
depression and T-wave inversion in leads II, III, and aVF 
(Fig. 4). Cardiac enzymes were also elevated (creatine 
kinase-MB 9.9 U/L, Troponin I 7.73 ng/mL, Troponin 
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T 2.64 ng/mL). The patient underwent emergency cor-
onary angiography, which revealed total occlusion of the 
DES in the proximal RCA due to very late stent throm-
bosis with grade II collateral flow (Fig. 5A and B). The 
BMS in the LAD was patent (Fig. 5C). After receiving 
an intravenous glycoprotein IIb/IIIa receptor blocker 
(abciximab), the patient underwent repeat balloon angio-
plasty and thrombus aspiration secondary to recurrent, 
immediate thrombus formation and coronary occlusion 
(Fig. 6A). The final angiogram showed good flow without 




We report this case to draw attention to the phenom-
enon of very late stent thrombosis after DES implanta-
tion, which might be associated with serious clinical im-
plications after the discontinuation of dual antiplatelet 
therapy. It is possible that DESs are associated with sub-
stantially higher rates of thrombosis when compared 
with BMSs. 
Stent thrombosis (ST) is a generally fatal complication 
after PCI. It may occur in the acute (<1 day), subacute 
(<30 days), late (<1 year), or very late (>1 year) periods 
and may result in serious complications such as MI and 
death.
5) Very late stent thrombosis (VLST) is defined as 
a stent thrombosis event that occurs beyond one year. 
The risk of VLST was analyzed using trial level data in a 
meta-analysis of 14 randomized trials in which 6,675 
patients had been randomly assigned to PCI with DES 
Fig. 2. The first follow-up coronary angiogram and percutaneous coronary intervention for restenosis. A: CAG revealed type III diffuse 
in-stent restenosis in the proximal left anterior descending artery (LAD) (arrow). B: plain balloon angioplasty was successfully performed 
for the treatment of in-stent restenosis in the LAD. CAG: coronary angiogram.  
B A 
Fig. 1. Diagnostic coronary angiogram and primary percutaneous intervention. A: CAG revealed total occlusion of the proximal left 
anterior descending artery (LAD) (arrow). B: a bare metal stent (3.5×28 mm Arthos Inert Stent) was successfully placed in the occluded 
LAD. CAG: coronary angiogram.  
B  A  
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or BMS.
6) The incidences of VLST were 5.0 events per 
1,000 patients in the DES group and 0 events per 1,000 
patients in the BMS group (relative risk=5.0, 95% con-
fidence interval 1.3-19.5). In another report, DESs were 
reported to have an approximately 0.3 to 0.5 percent 
greater risk of VLST compared with BMSs.
7) Several fac-
tors were shown to be associated with ST, including older 
age, black race, diabetes mellitus, bifurcation lesion, in-
stent restenosis lesion, post-procedure acute renal fail-
ure, and lack of clopidogrel therapy.
8) Discontinuation 
Fig. 4. Follow-up electrocardiographic finding. The ECG showed newly developed ST-segment depression and T-wave inversion in 
leads II, III, and aVF. ECG: electrocardio-gram. 
Fig. 3. The second follow-up coronary angiogram and percutaneous coronary intervention for de novo lesion in right coronary artery. A:
CAG revealed a patent LAD stent (arrow). B: near total occlusion of the proximal RCA was also detected (arrow). C: a TAXUS stent (2.75×
32 mm) was successfully implanted after dilation using a 2.5×20 mm balloon in the proximal RCA. CAG: coronary angiogram, LAD: left 
anterior descending artery, RCA: right coronary artery. 
C  B  A 
Fig. 5. The third follow-up coronary angiogram. A: total occlusion of the proximal right coronary artery at the level of the stent with evi-
dence of thrombosis. B: grade II collateral flow from the left coronary artery (arrow). C: left coronary angiogram revealed a patent bare 
metal stent in the left anterior descending artery (arrow). 
C  B  A  
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of antiplatelet therapy, as an independent predictor of 
stent thrombosis, even several years after DES implan-
tation, increases the risk of late stent thrombosis. This 
finding suggests that clopidogrel compliance may mini-
mize the incidence of VLST after DES implantation. 
Current recommendations suggest extending dual 
antiplatelet therapy beyond one year in patients with 
low bleeding risk. Antiplatelet treatment should be con-
tinued even if there is an increased risk of minor bleed-
ing complications so that life-threatening complications, 
such as acute MI, are avoided. Patients with previously 
implanted DESs who are currently taking dual antiplatelet 
therapy are at high risk for developing stent thrombosis 
when a situation arises that requires cessation or inter-
ruption of dual platelet inhibition.
9)10) 
The optimal duration of antiplatelet therapy in pa-
tients with coronary artery stents still remains to be de-
termined. Further large-scale studies are needed to de-
termine the optimal combination and duration of anti-
platelet therapy that should be used to prevent these 
serious thrombotic events.   
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Fig. 6. Percutaneous coronary intervention for the very late stent thrombosis in right coronary artery. A: a balloon angioplasty was per-
formed to treat total occlusion of the stented right coronary artery. B: final coronary angiogram showed good distal flow without residual 
stenosis. 
B  A 